Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Zhejiang Medicine Drops Price on Private Placement

publication date: Feb 13, 2012
Zhejiang Medicine reduced the price of an upcoming private placement from 27.98 RMB to 18.73 RMB per share, reflecting a drop in the company’s stock price. One year ago, Zhejiang was trading hands at over 38 RMB, but it has slipped to 22.60 currently. The price of the private placement represents a discount of about 17% to the market. Zhejiang, which makes antibiotics, vitamin H and carotene, will offer 70 million shares to raise 1.6 billion RMB ($254 million). More details....

Stock Symbol: (SHA: 600216)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital